“Off-The-Shelf” Third Party T Cells for CAR-T Therapy Under Investigation – Cancer Network
The Advertiser |
“Off-The-Shelf” Third Party T Cells for CAR-T Therapy Under Investigation
Cancer Network A matched donor with similar immunity is not required and neither are the patient’s own T cells. “We were able to efficiently (> 90%) delete both copies of CD7 and the T-cell receptor alpha subunit (TRAC) and insert a unique CAR to CD7 in human T cells … Adelaide’s Carina Biotech makes killer cells to cure cancerThe Advertiser |
EconoTimes |
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 …
Nasdaq NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases … Abeona’s ABO-202 nabs Rare Pediatric Disease Designation in US for Batten disease; shares up 4% premarketSeeking Alpha |